(Reuters) - Avanir Pharmaceuticals Inc said a late-stage trial of its neurological drug Zenvia showed encouraging proof of concept data in relieving pain associated with multiple sclerosis (MS), sending its shares up more than 16 percent.
Additional data from its STAR trial, which tested Zenvia as a treatment for pseudobulbar affect (PBA), showed that the 30/10 mg dose of the drug reduced MS-related pain in a small subset of patients with moderate-to-severe pain, Avanir said.
PBA is a condition in which patients cannot control outbursts of crying or laughing. It affects an estimated 2 million Americans with multiple sclerosis, Lou Gehrig's disease (ALS), stroke and other neurological diseases or trauma that can cause brain lesions.
Continue reading more of Avanir from this REUTERS news release
============================================
0 comments:
Post a Comment